$2.65
3.52% yesterday
NYSE, Aug 21, 10:11 pm CET
ISIN
US92332V1070
Symbol
VTYX

Ventyx Biosciences Stock price

$2.65
-0.30 10.17% 1M
+1.04 64.60% 6M
+0.46 21.00% YTD
+0.69 35.20% 1Y
-19.34 87.95% 3Y
-18.37 87.39% 5Y
-18.37 87.39% 10Y
-18.37 87.39% 20Y
NYSE, Closing price Thu, Aug 21 2025
+0.09 3.52%
ISIN
US92332V1070
Symbol
VTYX
Industry

Key metrics

Basic
Market capitalization
$189.0m
Enterprise Value
$-20.0m
Net debt
positive
Cash
$209.0m
Shares outstanding
71.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.9
Financial Health
Equity Ratio
91.9%
Return on Equity
-53.2%
ROCE
-59.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-129.1m | $-116.0m
EBIT
$-130.4m | $-146.6m
Net Income
$-119.0m | $-137.1m
Free Cash Flow
$-105.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
30.2% | 21.2%
EBIT
29.8% | 1.2%
Net Income
30.5% | -1.5%
Free Cash Flow
33.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.7
FCF per Share
$-1.5
Short interest
7.1%
Employees
81
Rev per Employee
$0.0
Show more

Is Ventyx Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Ventyx Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Ventyx Biosciences forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Ventyx Biosciences forecast:

Buy
79%
Hold
21%

Financial data from Ventyx Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
8% 8%
-
- Research and Development Expense 101 101
34% 34%
-
-129 -129
30% 30%
-
- Depreciation and Amortization 1.30 1.30
60% 60%
-
EBIT (Operating Income) EBIT -130 -130
30% 30%
-
Net Profit -119 -119
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about Ventyx Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ventyx Biosciences Stock News

Neutral
The Motley Fool
15 days ago
Ventyx Biosciences (VTYX -6.72%), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and neurodegenerative diseases, released its second-quarter 2025 results on August 7, 2025. EPS (GAAP) was $0.38, which exceeded the analyst consensus estimate of $(0.47) GAAP.
Neutral
GlobeNewsWire
15 days ago
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson's disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 Cash...
Neutral
GlobeNewsWire
2 months ago
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease
More Ventyx Biosciences News

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Raju Mohan
Employees 81
Founded 2018
Website ventyxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today